ClinicalTrials.gg
TerminatedNCT03326843Updated Apr 15, 2020Results posted

Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure

A Phase 3 interventional study of Avatrombopag 60 mg in Thrombocytopenia, sponsored by Sobi, Inc.. Terminated at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-15.

Sponsored by Sobi, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was terminated due to enrollment challenges.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing avatrombopag in Thrombocytopenia — 6 open to participants now, 6 under way, 2 of them phase 3. avatrombopag · Thrombocytopenia.

Enrollment
21st of 23
4 · median 50
Started
2018
with 1 other
Phase 3
5 of 23
1 open now
Registered
7th of 23
by date
Lead sponsor
2 of 23
Sobi, Inc.

Among the 23 studies testing avatrombopag in Thrombocytopenia, this one is the 21st largest by enrollment, is one of 2 that started in 2018, is one of 5 in phase 3, and was the 7th registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

6 of the 23 studies testing avatrombopag in Thrombocytopenia are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing avatrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding.

Read the detailed description

Subjects will receive oral avatrombopag once daily for 5 days beginning on Day 1, followed by a wait period prior to the procedure, which will occur on Day 10 to 13. The Follow-up Period will include 2 visits; 7 days post-procedure and 30 days after last dose.

03

Conditions studied

  • Thrombocytopenia

Browse trials for

Keywords

  • low platelet count
  • ITP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women greater than or equal to 18 years of age;
  • A mean baseline count between:

    • 50 × 10\^9/L and \<100 × 10\^9/L for non-chronic liver disease participants
    • 50 × 10\^9/L and \<75 × 10\^9/L for participants with chronic liver disease;
  • Participant is scheduled to undergo operations to critical sites (eg, eye surgery, neurosurgery) or operations with a high risk of bleeding (eg, major abdominal surgery), or, in the opinion of the Investigator, would otherwise require a pre-operative platelet transfusion to prevent bleeding

Exclusion criteria

Exclusion Criteria:

  • Participant with a history of arterial or venous thrombosis within 6 months of baseline;
  • Participant with known portal vein blood flow velocity rate \<10 cm/second or previous portal vein thrombosis within 6 months of baseline;
  • Participant plans to have a transfusion or plans to receive blood products containing platelets within 7 days of the Baseline Visit;
  • Use of erythropoietin-stimulating agents;
  • Participant has a known medical history of genetic prothrombotic syndromes; or
  • Participant has abnormal levels or /international normalized ratio
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Avatrombopag 60 mg

    Open-label: oral avatrombopag

    Drug: Avatrombopag 60 mg

Interventions

  • Oral avatrombopag administered once daily for 5 days prior to procedure.

06

What researchers measure

Primary outcomes

  1. Evaluate Efficacy of Avatrombopag in Increasing Platelet Counts in Subjects With Thrombocytopenia Scheduled for Operations

    Proportion of subjects that achieve a platelet count \>100 x 10\^9 platelets/L on procedure day

    Time frame: Baseline to 10-13 days

Secondary outcomes

  1. Evaluate Safety of Avatrombopag: Incidence of Treatment Emergent Adverse Events

    Incidence of treatment emergent adverse events

    Time frame: Up to 35 days

07

Results

Posted Apr 15, 2020

Participant flow

Participant flow — Overall Study
MilestoneAvatrombopag 60 mg
Started4
Completed4
Not completed0

Outcome measures

PrimaryEvaluate Efficacy of Avatrombopag in Increasing Platelet Counts in Subjects With Thrombocytopenia Scheduled for Operations

Proportion of subjects that achieve a platelet count \>100 x 10\^9 platelets/L on procedure day

Time frame:
Baseline to 10-13 days
Reported as:
Number · proportion of total participants
Evaluate Efficacy of Avatrombopag in Increasing Platelet Counts in Subjects With Thrombocytopenia Scheduled for Operations
proportion of total participantsAvatrombopag 60 mg
Evaluate Efficacy of Avatrombopag in Increasing Platelet Counts in Subjects With Thrombocytopenia Scheduled for Operations0.75
SecondaryEvaluate Safety of Avatrombopag: Incidence of Treatment Emergent Adverse Events

Incidence of treatment emergent adverse events

Time frame:
Up to 35 days

No measurements were reported for this outcome.

Adverse events

Collected over From the time of consent through study follow up visit, up to 35 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avatrombopag 60 mg0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Most frequent other events
EventAvatrombopag 60 mg
InfluenzaInfections and infestations1/4
Urinary Tract InfectionInfections and infestations1/4
Urinary RetentionRenal and urinary disorders1/4
GoutMetabolism and nutrition disorders1/4
Subcutaneous hematomaInjury, poisoning and procedural complications1/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Avatrombopag 60 mg
<=18 years0
Between 18 and 65 years1
>=65 years3
Age, Continuous
Age, Continuous(years)Avatrombopag 60 mg
Mean66 (51 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Avatrombopag 60 mg
Female2
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Avatrombopag 60 mg
Hispanic or Latino1
Not Hispanic or Latino3
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Avatrombopag 60 mg
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White3
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Avatrombopag 60 mg
United States4
Platelet Counts
Platelet Counts(10^9 platelets/L)Avatrombopag 60 mg
Mean68 (64 to 73)
08

Study locations

27 sites
  • Dova Site
    Little Rock, Arkansas 72205, United States
  • Dova Site
    Coronado, California 92118, United States
  • Dova Site
    Aurora, Colorado 80045, United States
  • Dova Site
    Jacksonville, Florida 32209, United States
  • Dova Site
    Jacksonville, Florida 32224, United States
  • Dova Site
    Miami, Florida 33135, United States
  • Dova Site
    Miami, Florida 33136, United States
  • Dova Site
    Pensacola, Florida 32503, United States
  • Dova Site
    Sarasota, Florida 34232, United States
  • Dova Site
    Tamarac, Florida 33321, United States
  • Dova Site
    Tampa, Florida 33615, United States
  • Dova Site
    New Orleans, Louisiana 70112, United States
  • Dova Site
    Baltimore, Maryland 21202, United States
  • Dova Site
    Boston, Massachusetts 02115, United States
  • Dova Site
    Detroit, Michigan 48202, United States
  • Dova Site
    Saint Louis, Missouri 63110, United States
  • Dova Site
    Springfield, Missouri 65807, United States
  • Dova Site
    Reno, Nevada 89503, United States
  • Dova Site
    Englewood, New Jersey 07631, United States
  • Dova Site
    Buffalo, New York 14203, United States
  • Dova Site
    Durham, North Carolina 27710, United States
  • Dova Site
    Winston-Salem, North Carolina 27157, United States
  • Dova Site
    Toledo, Ohio 43606, United States
  • Dova Site
    Bethlehem, Pennsylvania 18015, United States
  • Dova Site
    Austin, Texas 78731, United States
  • Dova Site
    Newport News, Virginia 23602, United States
  • Dova Site
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Feb 2019, 10 months.

Results were first posted in Apr 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2017
First posted
Oct 31, 2017
StartActual
Mar 26, 2018
Primary completionActual
Feb 25, 2019
CompletionActual
Feb 25, 2019
Results first posted
Apr 15, 2020
Last update
Apr 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03326843
Lead sponsor
Sobi, Inc.
Responsible party
Sponsor
First posted
Oct 31, 2017
Start date
Mar 26, 2018
Primary completion
Feb 25, 2019
Completion
Feb 25, 2019
Results posted
Apr 15, 2020
Last update
Apr 15, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion